Filing Flows

Filing Flows › Companies › Korro Bio › Cash flow

Korro Bio cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$13.0M in Q3 2026 · −$63.9M over twelve months

Operating cash flow−$12.9M
Capital spending−$27K
Free cash flow−$13.0M

Analysis

In Q3 2026, Korro Bio generated −$12.9M of operating cash flow and spent $27K on capital projects, leaving free cash flow of −$13.0M. That is $4.4M more than in Q3 2025 (−$17.4M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$63.7M; the largest uses were operating cash flow ($63.7M), other investing ($6.8M), capital spending ($169K); besides operations, cash came from other financing ($85.3M), shares issued ($397K); the cash balance rose by $15.1M.

Operating cash flow was −$12.9M against net income of −$17.5M. The largest differences: stock-based pay +$2.8M, prepaid and other assets +$1.7M, accrued liabilities +$492K.

Free cash flow

Korro Bio: free cash flow by quarterKorro Bio: free cash flow by quarter−$8.9MQ4 2024−$24.6MQ1 2025−$19.4MQ2 2025−$17.4MQ3 2025−$17.8MQ4 2025−$16.1MQ1 2026−$17.0MQ2 2026−$13.0MQ3 2026
Operating cash flow less capital spending.
Korro Bio: operating cash flow against capital spendingKorro Bio: operating cash flow against capital spendingOperating cash flowCapital spending−$7.5M$1.5MQ4 2024−$24.5M$119KQ1 2025−$19.2M$140KQ2 2025−$17.2M$175KQ3 2025−$17.7M$84KQ4 2025−$16.1M$21KQ1 2026−$17.0M$37KQ2 2026−$12.9M$27KQ3 2026
Latest (Q3 2026): Operating cash flow −$12.9M, Capital spending $27K.

Capital allocation, year by year

Korro Bio: where the cash came from (up) and went (down), by fiscal yearKorro Bio: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$76.1MFY2021: Shares issued $1.4MFY2021: Capital spending −$2.9M$1.4MFY2021FY2022: Operating cash flow −$53.6MFY2022: Net borrowing −$833KFY2022: Shares issued $62KFY2022: Capital spending −$5.1M$62KFY2022FY2023: Operating cash flow −$67.3MFY2023: Shares issued $118MFY2023: Capital spending −$7.8M$118MFY2023FY2024: Operating cash flow −$60.1MFY2024: Shares issued $2.0MFY2024: Capital spending −$17.9M$2.0MFY2024FY2025: Operating cash flow −$78.6MFY2025: Shares issued $685KFY2025: Capital spending −$518K$685KFY2025
Over these 5 years operating cash flow totalled −$336M; the largest uses were operating cash flow ($336M) and capital spending ($34.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$105M
Debtnone
Net cash$105M
Cash runway20 months

Korro Bio is burning cash: its operations consume cash, a free cash flow of −$63.9M a year at the current rate against $105M of cash and investments: a runway of about 20 months before any new financing.

Where the cash came from and went

Korro Bio: sources (+) and uses (−) of cash, Q3 2026Korro Bio: sources (+) and uses (−) of cash, Q3 2026Other investing$28.3MCash drawn (+) / kept (−)−$15.3MOperating cash flow−$12.9MCapital spending−$27KExchange rates−$14K
Korro Bio: sources (+) and uses (−) of cash, TTM to Q3 2026Korro Bio: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$85.3MOperating cash flow−$63.7MCash drawn (+) / kept (−)−$15.1MOther investing−$6.8MShares issued$397KCapital spending−$169KExchange rates$58K

From profit to cash

Korro Bio: net income to operating cash flow, Q3 2026Korro Bio: net income to operating cash flow, Q3 2026Net income−$17.5MDepreciation & amortization$400KStock-based pay$2.8MGains on disposals$7KPayables−$410KAccrued liabilities$492KPrepaid and other assets$1.7MOperating cash flow−$12.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$12.9M−$27K—−$15.3M−$13.0M
Q2 2026−$17.0M−$37K−$2.9M$37.8M−$17.0M
Q1 2026−$16.1M−$21K$83.2M−$39.9M−$16.1M
Q4 2025−$17.7M−$84K$380K$2.3M−$17.8M
Q3 2025−$17.2M−$175K$128K$9.5M−$17.4M
Q2 2025−$19.2M−$140K$5K$30.5M−$19.4M
Q1 2025−$24.5M−$119K$172K−$8.5M−$24.6M
Q4 2024−$7.5M−$1.5M−$66.5M$9.3M−$8.9M

Korro Bio: income statement and cash flow

Korro Bio, Q4 2025: revenue $1.3M (-43% year over year). The chart follows the revenue to costs, profit and cash.

Korro Bio: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.